Sinopia Biosciences, Inc.
Sinopia Biosciences is a data-driven drug discovery company focused on developing novel therapeutics through advanced computational platforms that integrate high-throughput omics data, AI/machine learning, and network biology. Their mission is to enable safer and more effective therapeutics by leveraging big data and innovative technologies to understand disease mechanisms and identify promising drug candidates.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Integrated multi-omics and machine learning discovery platform
A discovery platform that integrates high-throughput multi-omics data generation, machine learning, network analysis, and phenotypic screening to identify disease signatures, targets, and candidate compounds.
Small-molecule clinical candidate (Parkinson's disease)
A proprietary small-molecule program identified through integrated multi-omics and computational analyses and advanced through IND-enabling preclinical studies toward clinical entry for Parkinson's disease indications.
Preclinical therapeutic candidates for oral mucositis
Therapeutic candidates and target hypotheses for oral mucositis derived from multi-omics analysis and preclinical in vivo data, advanced under government grant funding for further development.
Integrated multi-omics and machine learning discovery platform
A discovery platform that integrates high-throughput multi-omics data generation, machine learning, network analysis, and phenotypic screening to identify disease signatures, targets, and candidate compounds.
Small-molecule clinical candidate (Parkinson's disease)
A proprietary small-molecule program identified through integrated multi-omics and computational analyses and advanced through IND-enabling preclinical studies toward clinical entry for Parkinson's disease indications.
Preclinical therapeutic candidates for oral mucositis
Therapeutic candidates and target hypotheses for oral mucositis derived from multi-omics analysis and preclinical in vivo data, advanced under government grant funding for further development.
Services
Partnered research engagements that apply integrated multi-omics experiments, machine learning, and network analysis to identify targets and prioritize compounds for therapeutic development.
High-throughput metabolomics screening workflows integrated with mass spectrometry data generation and computational interpretation to assess compound and genetic perturbation effects.
Non-clinical candidate selection and execution of IND-enabling studies, including pharmacology and safety-directed preclinical work to prepare candidates for clinical entry.
Discovery and multi-site validation of metabolite biomarker panels relevant to red blood cell and platelet storage quality and related translational studies.
Partnered research engagements that apply integrated multi-omics experiments, machine learning, and network analysis to identify targets and prioritize compounds for therapeutic development.
High-throughput metabolomics screening workflows integrated with mass spectrometry data generation and computational interpretation to assess compound and genetic perturbation effects.
Non-clinical candidate selection and execution of IND-enabling studies, including pharmacology and safety-directed preclinical work to prepare candidates for clinical entry.
Discovery and multi-site validation of metabolite biomarker panels relevant to red blood cell and platelet storage quality and related translational studies.
Expertise Areas
- Data-driven drug discovery
- Metabolomics and mass spectrometry-based discovery
- Machine learning and AI for biomedical data
- Systems biology and network analysis
Key Technologies
- Metabolomics (mass spectrometry)
- High-throughput screening (HTS)
- Machine learning / artificial intelligence
- Network biology / systems biology
News & Updates
Sinopia Biosciences received a Phase II SBIR grant to advance its therapeutic candidates for oral mucositis, a side effect of chemotherapy and radiotherapy. The grant supports the development of novel drugs using their LEADS platform, which employs AI and multi-omics data analysis.
Sinopia Biosciences was awarded an NIH grant to support the development of its lead program for Parkinson’s disease, including advancing its small molecule candidate SB-0107 into clinical trials. The company uses its proprietary LEADS platform for drug discovery.
Sinopia received a grant to develop and validate a metabolomics-based high-throughput screening platform for drug discovery, focusing on rare diseases and expanding its capabilities in analyzing cellular effects of compounds.
Sinopia received a grant to study the metabolic changes in stored red blood cells and develop methods to better preserve them for transfusion, using systems biology and metabolomics analysis.
Sinopia was awarded a research grant to support the development of its small molecule SB-0107 for Parkinson’s disease, demonstrating its platform’s ability to identify promising therapeutic candidates.
Sinopia Biosciences received a grant to develop therapeutics for oral mucositis, a side effect of cancer therapy, using its AI-driven platform to identify novel targets and compounds.
Sinopia Biosciences received a Phase II SBIR grant to advance its therapeutic candidates for oral mucositis, a side effect of chemotherapy and radiotherapy. The grant supports the development of novel drugs using their LEADS platform, which employs AI and multi-omics data analysis.
Sinopia Biosciences was awarded an NIH grant to support the development of its lead program for Parkinson’s disease, including advancing its small molecule candidate SB-0107 into clinical trials. The company uses its proprietary LEADS platform for drug discovery.
Sinopia received a grant to develop and validate a metabolomics-based high-throughput screening platform for drug discovery, focusing on rare diseases and expanding its capabilities in analyzing cellular effects of compounds.
Sinopia received a grant to study the metabolic changes in stored red blood cells and develop methods to better preserve them for transfusion, using systems biology and metabolomics analysis.
Sinopia was awarded a research grant to support the development of its small molecule SB-0107 for Parkinson’s disease, demonstrating its platform’s ability to identify promising therapeutic candidates.
Sinopia Biosciences received a grant to develop therapeutics for oral mucositis, a side effect of cancer therapy, using its AI-driven platform to identify novel targets and compounds.